Search Results
Jan 13, 2026, 08:38 ET NOW® Survey Uncovers The Wellness And Health Priorities Shaping Consumers' Supplement Use In 2026
probiotic (NOW is one of the only supplement companies to test for exact DNA strains via their RiboPrinter technology).Additional Wellness Priorities and Supplements to Consider:Immune Health*:
More news about: NOW®
Jan 13, 2026, 08:00 ET Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026
More news about: Ginkgo Bioworks
Jan 13, 2026, 07:07 ET Leo International Group Relocates Global Headquarters to Singapore Ahead of Its Centennial
American corporations that had survived wars, industrial shifts, technological disruption and changing consumer values, my experience taught me this: the DNA of a century-old enterprise must be etched with discipline and altruism because if those remain intact, the organisation can navigate change without
More news about: Leo International Group
Jan 13, 2026, 07:00 ET Identiv Recognized for Internet-of-Things Innovation in 10th Annual IoT Breakthrough Awards Program
immutable link between physical products and their digital twins. At the core are Identiv's tamper-detecting NFC inlays, powered by NXP®'s NTAG® 424 DNA TagTamper security chips, which detect interference and connect each bottle to its digital identity."For businesses and buyers, protecting authenticity
More news about: Identiv
Jan 13, 2026, 07:00 ET Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
non-small cell lung cancer.MRD testing helps clinicians track a patient's risk of cancer recurrence by detecting small traces of circulating tumor DNA (ctDNA) in a patient's bloodstream following treatment. This can signal molecular recurrence months before clinical relapse appears on traditional imaging
More news about: Labcorp
Jan 13, 2026, 03:00 ET n-Lorem und EspeRare kündigen europäische Zusammenarbeit zur Erweiterung des Zugangs zu individualisierten ASO-Therapien für seltene genetische Erkrankungen an
n-Lorem wurde gegründet, um diesen Patienten Hoffnung zu geben, indem individualisierte ASO-Therapien entwickelt werden – kurze Stränge modifizierter DNA, die präzise auf die Transkripte eines defekten Gens abzielen, um die Anomalie zu korrigieren. Diese experimentellen Therapien haben den Vorteil, schnell,
More news about: EspeRare Foundation
Jan 12, 2026, 16:19 ET Stellantis Puts Customer Choice Front and Center at the 2026 Detroit Auto Show With New Vehicles, Iconic Returns and Interactive Experiences
precise control from the first touch of the throttle, accelerating from 0 to 60 mph in as little as 3.6 seconds. It's a bold, new expression of Jeep brand DNA, electrified and trail ready with an estimated all-electric range of up to 250 miles (based on trim). In November in honor of the
More news about: Stellantis
Jan 12, 2026, 16:07 ET Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026
IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jan 12, 2026, 13:43 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they
More news about: EspeRare Foundation
Jan 12, 2026, 10:00 ET Basecamp Research 推出全球首創可編程基因插入人工智能模型
表示：「我們相信，癌症與遺傳性疾病患者的治療前景正迎來重大突破的開端。透過運用 AI 設計治療性酵素，我們期望加速開發數千種無法治癒疾病的療法，有望為數百萬人的生命帶來轉變。」可編程基因插入可編程基因插入——將大型治療性 DNA 序列精確置入人類基因組特定位置——數十年來始終是基因醫學的核心目標。現有的基於 CRISPR 的技術僅能進行微小編輯，且必須破壞 DNA 方能實現，這限制了其應用範圍與方式。Basecamp Research 率先證明 AI 能設計出可在人類基因組特定位置執行大規模基因插入的酵素，為可編程療法開闢了長期尋求的途徑。Basecamp Research
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection
collaborating to train and optimize an FLDL model to address the challenge of the very large datasets – millions of tumor-derived cell-free DNA (cfDNA) fragments and billions of DNA base pairs – derived from a single blood draw. As Freenome scales commercial testing to reach the millions of people eligible for
More news about: Freenome Holdings, Inc.
Jan 12, 2026, 10:00 ET Basecamp Research launches world-first AI models for programmable gene insertion
gene insertion - placing large therapeutic DNA sequences at precise locations in the human genome - has been a central goal in genetic medicine for decades. Existing CRISPR-based approaches can only make small edits and must damage DNA to do so, limiting where and how they can be used.
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Basecamp Research launches world-first AI models for programmable gene insertion
gene insertion - placing large therapeutic DNA sequences at precise locations in the human genome - has been a central goal in genetic medicine for decades. Existing CRISPR-based approaches can only make small edits and must damage DNA to do so, limiting where and how they can be used.
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Basecamp Research bringt weltweit erste KI-Modelle für die programmierbare Gen-Insertion auf den Markt
Platzierung großer therapeutischer DNA-Sequenzen an präzisen Stellen im menschlichen Genom – ist seit Jahrzehnten ein zentrales Ziel der Genmedizin. Bestehende CRISPR-basierte Ansätze können nur kleine Änderungen vornehmen und müssen dazu die DNA beschädigen, was ihre Einsatzmöglichkeiten
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET Basecamp Research lança modelos de IA pioneiros no mundo para inserção programável de genes
colocar sequências terapêuticas de DNA grande em locais precisos no genoma humano – tem sido um objetivo central na medicina genética por décadas. Abordagens baseadas em CRISPR existentes só conseguem fazer pequenas edições e precisam danificar o DNA para isso, limitando onde e como podem
More news about: Basecamp Research
Jan 12, 2026, 10:00 ET 베이스캠프 리서치, 세계 최초 프로그램 가능한 유전자 삽입 AI 모델 출시
삽입 인간 유전체의 정밀한 위치에 대규모 치료용 DNA 염기서열을 배치하는 프로그램 가능한 유전자 삽입은 지난 수십 년간 유전 의학의 핵심 목표였다. 기존의 크리스퍼(CRISPR) 기반 방식은 작은 일부만 편집이 가능하며 DNA 손상이 불가피했기 때문에 사용 위치와 방식에 한계가 있었다. 베이스캠프 리서치는 AI가 인간 유전체의 특정 부위에 대규모 유전자 삽입을 수행할 수 있는 효소를 설계할 수 있음을 최초로
More news about: Basecamp Research
Jan 12, 2026, 09:00 ET Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to
More news about: Co-Diagnostics
Jan 12, 2026, 09:00 ET NORWEGIAN CRUISE LINE DEBUTS NEW BRAND PLATFORM, "IT'S DIFFERENT OUT HERE," AND LAUNCHES NATIONAL AD CAMPAIGN
transformation honors that legacy while meeting the expectations of today's guests. Delivering on this vision takes trusted partners who understand our DNA, and Arnold has helped us bring it to life in a way that is authentic, and unmistakably NCL."The centerpiece of the national effort to bring the
More news about: Norwegian Cruise Line
Jan 12, 2026, 08:00 ET Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
TestingPatients who have received LYFGENIA are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to integrated BB305 LVV proviral DNA, resulting in a possible false-positive PCR assay test result for HIV. Therefore, patients who have received LYFGENIA should not be screened for HIV
More news about: Minaris Advanced Therapies
Jan 12, 2026, 04:00 ET WePlay Partners with Türk Eğitim Derneği (TED) to Support 86 Students in Pursuing Their Dreams
regions and communities;Integrating corporate social responsibility into product innovation, making "technology for good" part of the platform's DNA.As TED believes—education changes lives, and WePlay is taking action to change the futures of millions of students.About WePlayWePlay
More news about: WEJOY PTE. LTD.; WePlay
Jan 11, 2026, 12:00 ET IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
submission to the U.S. Food and Drug Administration (FDA) and/or NCCN/compendia listing in this patient subsetAntibody-drug Conjugate (ADC) + DNA damage response (DDR) combinationsIDE849 (DLL3 TOP1 ADC): target to initiate a monotherapy registrational study in the second
More news about: IDEAYA Biosciences, Inc.
Jan 11, 2026, 09:58 ET Authentic Brands Group Taps Google Cloud and Gemini to Power the Future of Brand Building with AI
inspiration can quickly become a global campaign—all while ensuring every piece of content, from SHAQ to Reebok and Juicy Couture, stays true to the brand's DNA."About Authentic Brands Group Authentic Brands Group (Authentic) is a leading sports, media, entertainment and lifestyle platform.
More news about: Google Cloud
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
or FOLFIRI in anti-EGFR-naïve RAS/BRAF WT mCRC. Eligible patients were wild-type (WT) for KRAS, NRAS or BRAF genes based on circulating tumor DNA testing. Additionally, patients were required to have no amplification of the ERBB2/HER2 gene. In the RYBREVANT® and chemotherapy cohorts,
More news about: Johnson & Johnson
Jan 09, 2026, 13:00 ET Tulsa's Route 66 Capital Cruise will be official GUINNESS WORLD RECORDS™ Attempt
Tulsa," said Lobeck Taylor Family Foundation Chief Executive Officer Brian Paschal. "Route 66 is central to Tulsa's identity and a crucial part of our DNA, and setting a world record on the Mother Road in Tulsa during the Centennial year will be a true unprecedented celebration."The Cruise will take
More news about: Visit Tulsa
Jan 09, 2026, 08:16 ET Aily Labs startet „Lead Boldly" („Entschlossen führen") - einen neuen Aufruf zu entschlossener Führung im Zeitalter der KI
BAFTA-nominierten englischen Filmregisseur, der Drehbücher für Dramen, Dokumentarfilme und Werbespots geschrieben und Regie geführt hat. Getreu der AI-first-DNA von Aily wurde die Kampagne mit den neuesten AI-gestützten virtuellen Produktionstechniken erstellt: AI erzählt die Geschichte von AI-gesteuerter Führung.Weitere
More news about: Aily Labs